

AquaBounty Technologies, Inc.
Form SC 13G/A
February 14, 2019

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

(Amendment No. 2)

(Rule 13d-102)

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO §240.13(d)-1(b), (c) and (d) AND AMENDMENTS THERETO FILED
PURSUANT TO §240.13d-2**

AquaBounty Technologies, Inc.

(Name of Issuer)

Common Stock, Par Value \$0.001 Per Share

(Title of Class of Securities)

UO387J108

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

Edgar Filing: AquaBounty Technologies, Inc. - Form SC 13G/A

CUSIP No. UO387J108

13G

1. Names of Reporting Persons
Abbott Laboratories (I.R.S. Identification No. 36-0698440)
 2. Check the Appropriate Box if a Member of a Group
(a)
(b)
 3. SEC Use Only
 4. Citizenship or Place of Organization
Illinois
- | | | | |
|---|--|--|---------|
| | 5. | Sole Voting Power | -0- |
| Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 6. | Shared Voting Power | 687,804 |
| | 7. | Sole Dispositive Power | -0- |
| | 8. | Shared Dispositive Power | 687,804 |
| | 9. | Aggregate Amount Beneficially Owned by Each Reporting Person | 687,804 |
| 10. | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="radio"/> | | |
| 11. | Percent of Class Represented by Amount in Row (9)
4.56% | | |
| 12. | Type of Reporting Person
CO | | |

CUSIP No. UO387J108

13G

- | | |
|-----|---|
| 1. | Names of Reporting Persons
Abbott Laboratories (Chile) Holdco SpA |
| 2. | Check the Appropriate Box if a Member of a Group
(a) <input type="radio"/>
(b) <input checked="" type="radio"/> |
| 3. | SEC Use Only |
| 4. | Citizenship or Place of Organization
Chile |
| 5. | Sole Voting Power
-0- |
| 6. | Shared Voting Power
677,407 |
| 7. | Sole Dispositive Power
-0- |
| 8. | Shared Dispositive Power
677,407 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
677,407 |
| 10. | Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares <input type="radio"/> |
| 11. | Percent of Class Represented by Amount in Row (9)
4.49% |
| 12. | Type of Reporting Person
CO |

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

Item 1(a). Name of Issuer:
AquaBounty Technologies, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
2 Mill & Main Place, Suite 395

Maynard, Massachusetts 01754

Item 2(a) (c). Name, Address and Citizenship of Persons Filing:
Abbott Laboratories

100 Abbott Park Road

Abbott Park, Illinois 60064

United States

Abbott Laboratories (Chile) Holdco SpA

Avenida Pedro de Valdivia No 295

Comuna de Providencia

Ciudad de Santiago Region Metropolitana

7500524 Chile

Item 2(d). Chile
Title of Class of Securities:
Common Stock, par value \$0.001 per share

Item 2(e). CUSIP Number:
UO387J108

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or (c), check which person filing is a:

- | | | |
|-----|-----------------------|---|
| (a) | <input type="radio"/> | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| (b) | <input type="radio"/> | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| (c) | <input type="radio"/> | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| (d) | <input type="radio"/> | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| (e) | <input type="radio"/> | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
| (f) | <input type="radio"/> | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
| (g) | <input type="radio"/> | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
| (h) | <input type="radio"/> | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| (i) | <input type="radio"/> | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
| (j) | <input type="radio"/> | Group, in accordance with Rule 13d-1(b)(1)(ii)(J). |

Item 4.

Ownership.

The information in items 1 through 12 on the cover pages (pages 2 and 3) of this statement is incorporated herein by reference.

The percentage ownership is calculated based on 15,098,837 shares of Common Stock issued and outstanding as of November 1, 2018, as disclosed by AquaBounty Technologies, Inc. in its Quarterly Report on Form 10-Q for the quarterly period ended september 30, 2018 filed with the Securities and Exchange Commission on November 2, 2018.

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following x.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Abbott Laboratories (Chile) Holdco SpA, a share corporation (*sociedad por acciones*) organized under the laws of Chile, is an indirect, wholly-owned subsidiary of Abbott Laboratories. Abbott Laboratories (Chile) Holdco SpA is the successor in interest to CFR International SpA. The information regarding the shares of AquaBounty Technologies, Inc. held by Abbott Laboratories (Chile) Holdco SpA in items 1 through 12 on the cover pages (page 2) of this statement is incorporated herein by reference.

Western Pharmaceuticals SA, a corporation (*sociedad anónima*) organized under the laws of Ecuador and an indirect, wholly-owned subsidiary of Abbott Laboratories, holds an additional 10,397 shares of Common Stock of AquaBounty Technologies, Inc. Western Pharmaceuticals SA is subject to liquidation proceedings and voting and dispositive control over such shares is exercised by a liquidator appointed pursuant to Ecuadoran law.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10. **Certifications.**
Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2019

ABBOTT LABORATORIES

By: /s/ Brian B. Yoor*
Name: Brian B. Yoor
Title: Executive Vice President, Finance and
 Chief Financial Officer

Abbott Laboratories (Chile) Holdco SpA

By: /s/ Brian B. Yoor*
Name: Brian B. Yoor
Title: Authorized Signatory

* By Jessica H. Paik, Attorney-in-Fact.